We are IntechOpen,
the world's leading publisher of Open Access books
Built by scientists, for scientists

6,900
Open access books available

185,000
International authors and editors

200M
Downloads

154
Countries delivered to

Our authors are among the

TOP 1%
most cited scientists

12.2%
Contributors from top 500 universities

BOOK CITATION INDEX
CLARIVATE ANALYTICS
INDEXED

WEB OF SCIENCE™

Selection of our books indexed in the Book Citation Index
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com

The Role of MicroRNAs in Estrogen Receptor α-Positive Human Breast Cancer

Hiroko Yamashita, Tatsuya Toyama, Nobuyasu Yoshimoto,
Yumi Endo, Mai Iwasa and Yoshitaka Fujii
Oncology, Immunology and Surgery,
Nagoya City University Graduate School of Medical Sciences,
Japan

1. Introduction

MicroRNAs (miRNAs) are a class naturally occurring small non-coding RNAs that control gene expression by targeting mRNAs for translational repression or cleavage (Krol et al., 2010). Recent evidence has shown that miRNA mutations or mis-expression correlate with various human cancers, and that loss- or gain-of function of specific miRNAs contributes to breast epithelial cellular transformation and tumorigenesis (Esquela-Kerscher et al., 2006). miRNA expression profiling also revealed that miRNAs are differently expressed among molecular subtypes in breast cancer (Blenkiron et al., 2007; Iorio et al., 2005).

There are large-scale molecular differences between estrogen receptor (ER) α-positive and ERα-negative breast cancers (Perou et al., 2000; Sorlie et al., 2003). Endocrine therapy has become the most important treatment option for women with ERα-positive breast cancer, and approximately 70% of primary breast cancers express ERα. ERα is essential for estrogen-dependent growth, and its level of expression is a crucial determinant of response to endocrine therapy and prognosis in ERα-positive breast cancer (Dowsett et al., 2008; Harvey et al., 1999; Yamashita et al., 2006). Multiple mechanisms involved in altering ERα gene expression in breast cancer have been proposed, including ERα gene amplification (Holst et al., 2007) as well as transcriptional silencing by DNA methylation of CpG islands within the ERα promoter (Giacinti et al., 2006) and mutations within the open reading frame of ERα (Herynk et al., 2004). However, expression levels of ERα in breast cancer tissues differ widely among patients (Yamashita et al., 2011), and frequently change during disease progression and in response to systemic therapies (Yamashita et al., 2009). It was reported that the microRNA miR-206 decreases endogenous ERα mRNA and protein levels in human MCF-7 breast cancer cells via two specific target sites within the 3'-untranslated region (UTR) of the human ERα transcript (Adams et al., 2007). We found that the expression levels of miR-206 were gradually decreased as ERα protein expression increased in breast cancer tissues, suggesting that miR-206 is a key factor for the regulation of ERα expression in human breast cancer (Kondo et al., 2008). Moreover, recent studies have shown that ERα-regulating miRNAs, miR-18a, miR-18b, miR-22, miR-193b, miR-302c, and miR-221/222, as well as miR-206, directly targeted ERα in 3'UTR reporter assays, and suggested that several miRNAs regulate ERα expression.

2. Estrogen receptor (ER) α expression in human breast cancer

2.1 Expression of ERα in human breast cancer tissues

2.1.1 ERα expression in normal and malignant breast epithelial cells

ERα expression in normal and premalignant breast epithelial cells has been assessed by immunohistochemistry. It was reported that on average, normal premenopausal terminal duct lobular units contain about 30% ERα-positive cells (Allred et al., 2004). In contrast, nearly all cells express very high levels of ERα in the majority of premalignant breast lesions, including atypical ductal hyperplasia, atypical lobular hyperplasia and lobular carcinoma in situ. DCIS (Ductal carcinoma in situ) shows various levels of ERα expression ranging from high levels of lower-grade lesions to low levels of higher-grade lesions, including entirely ERα-negative. Furthermore, the wide range of ERα expression is observed in invasive ductal carcinoma. There is a substantial (~25%) subset of invasive breast cancers that does not contain any ERα-expressing cells. The majority (~75%) of invasive breast cancers, however, does contain ERα-expressing cells, but the proportion varies ranging from very low, to intermediate, to very high. We examined ERα expression in breast cancer tissues by immunohistochemistry using Allred score (Allred et al., 1998), and demonstrated that breast tumors show a wide range of ERα expression levels (Yamashita et al., 2011). Moreover, intensity of ERα expression is not equal among breast cancer cells in an individual tumor. Eastern cooperative oncology group compared the distribution of ERα protein expression by immunohistochemistry and ERα mRNA expression by quantitative reverse transcription (RT)-PCR in ECOG 2197 study (Badve et al., 2008). They reported that ERα mRNA expression in breast cancer tissues also showed continuous and the wide range.

2.1.2 Role of expression levels of ERα in human breast cancer

It is well established that expression levels of ERα govern response to endocrine therapy and prognosis in ERα-positive human breast cancer. Allred and colleagues first reported that expression levels of ERα assessed by immunohistochemistry affected prognosis (Harvey et al., 1999). ERα status using Allred score was a highly significant predictor of disease-free survival for patients who received adjuvant endocrine therapy. Recently, relationship between expression levels of ERα and prognosis was analyzed in adjuvant endocrine therapy trials for postmenopausal breast cancer, and demonstrated that disease-free survival or time to recurrence were significantly different according to expression levels of ERα (Dowsett et al., 2008; Viale et al., 2007). It was reported that the use of a cutoff of 1% staining cells for ERα indicated a better prognosis and at least some degree of endocrine responsiveness (Hammond et al., 2010). In the neoadjuvant endocrine therapy trial for postmenopausal women, correlation between expression levels of ERα assessed by Allred score and response to neoadjuvant endocrine therapy was analyzed (Ellis et al., 2001). It showed that letrozole response rates were superior to tamoxifen response rates in every ERα Allred score from 3 to 8, indicating that letrozole is more effective than tamoxifen regardless of the level of ERα expression. We also studied expression levels of ERα on pretreatment biopsies and post-treatment surgical specimens in postmenopausal patients with ERα-positive primary breast cancer who were treated with aromatase inhibitors for 6 months (Yamashita et al., 2009). We showed that ERα expression was decreased in post-treatment tumors compared to pretreatment specimens. On the other hand, we analyzed expression levels of ERα in primary breast cancer specimens from 75 metastatic breast cancer patients who received endocrine therapy on relapse, and analyzed the correlation between

expression levels of ERα and response to endocrine therapy and post-relapse survival (Yamashita et al., 2006). Our results indicated that patients with higher ERα expression responded significantly to endocrine therapy, and that patients with higher ERα expression had better survival after relapse. Moreover, we recently reported that patients whose breast tumors contained high ERα expression effectively responded to aromatase inhibitors and displayed longer time to progression during first-line endocrine therapy with aromatase inhibitors and time to endocrine therapy failure (Endo et al., 2011).

2.2 Regulation of expression levels of ERα

Multiple mechanisms involved in the regulation of ERα expression in breast cancer have been identified, including mutations of ERα gene (Herynk et al., 2004) and transcriptional silencing by DNA methylation within the ERα promoter (Gaudet et al., 2009; Giacinti et al., 2006; Iwase et al., 1999). It was recently reported ERα gene amplification in breast cancer (Holst et al., 2007; Tomita et al., 2009). Holst and colleagues demonstrated that ERα gene amplification was frequent and more than 20% of breast cancers harbored genomic amplification by FISH analysis. They reported that ESR1 amplification was tightly linked to ERα protein expression, and that ESR1 amplification was also found in benign and precancerous breast diseases, such as atypical ductal hyperplasia, ductal carcinoma in situ and lobular carcinoma in situ. However, breast cancer patients show a wide range of ERα expression levels (Yamashita et al., 2011), and the levels of expression in individual patients change during disease progression and in response to systemic therapies (Yamashita et al., 2009). Therefore, other mechanisms may also regulate ERα expression in breast cancer.

2.2.1 miRNA biogenesis and function

MicroRNAs (miRNAs) comprise a large family of ~21-nucleotide-long RNAs that have emerged as key post-transcriptional regulators of gene expression (Krol et al., 2010). In mammals, miRNAs are predicted to control the activity of ~50% of all protein-coding genes. Functional studies indicate that miRNAs participate in the regulation of almost every cellular process investigated so far and that changes in their expression are associated with many human pathologies. Primary miRNA transcripts are cleaved into 70- to 80-nucleotide precursor miRNA (pre-miRNA) hairpins by RNase III Drosha in the cell nucleus and transported to the cytoplasm, where pre-miRNAs are processed by RNA Dicer into 19- to 25-nucleotide miRNA duplexes. One strand of each duplex is degraded, and the other strands become mature miRNAs, which, incorporated into the RNA-induced silencing complex, recognize sites in the 3'-UTR of the target mRNAs and cause translational repression or mRNA cleavage. miRNAs are a new player among gene regulation mechanisms, and their functions have not been fully explored but are known to include the regulation of cellular differentiation, proliferation and apoptosis. Recent evidence has shown that miRNA mutations or mis-expression are associated with various human cancers (Esquela-Kerscher et al., 2006).

2.2.2 Regulation of expression levels of ERα by miRNAs

Adams and colleagues first identified two potential miRNA miR-206 target sites within the 3'-UTR of ERα mRNA via in Silico analysis (Adams et al., 2007). The validation assay revealed that both miR-206 target sites specifically interacted with miR-206, which in turn repressed the corresponding ERα mRNA and protein expression. They also demonstrated

that expression levels of endogenous miR-206 were significantly higher in ERα-negative MDA-MB-231 cells than in ERα-positive MCF-7 cells. Moreover, they showed that miR-206 repressed ERα mRNA and protein expression in MCF-7 and T47D cells. We showed that miR-206 expression assayed by quantitative RT-PCR analysis was inversely correlated with ERα but not ERβ mRNA expression in human breast cancer tissues (Kondo et al., 2008). Moreover, miR-206 expression levels were gradually decreased as ERα protein expression increased in human breast cancer. Transfection experiments revealed that introduction of miR-206 in estrogen dependent MCF-7 cells inhibited cell growth. Transfection of miR-206 into MCF-7 cells suppressed ERα expression and inhibited cell growth in a dose-dependent manner. Furthermore, introduction of miR-206 produced a dose-dependent decrease of mRNA expression of ERα-target genes, such as progesterone receptor, cyclin D1 and pS2. Adams and colleagues recently reported that miR-206 coordinately targeted mRNAs encoding the coactivator proteins SRC-1 and SRC-3, and the transcription factor GATA-3, all of which contribute to estrogenic signaling and a luminal A phenotype (Adams et al., 2009). Furthermore, they identified that miR-206 contributed to the epidermal growth factor (EGF) induced repression of ERα signaling in MCF-7 cells.

2.2.3 MiRNAs that directly target ERα in human breast cancer

Zhao and colleagues demonstrated that miR-221 and miR-222 were highly expressed in ERα-negative breast cancer cells, and that miRNA in situ hybridization analyses also showed overexpression of miR-221 and miR-222 in ERα-negative breast tumors (Zhao et al., 2008). Recently, two groups reported several miRNAs that down-regulated ERα in breast cancer cells. They identified the target sites of miRNAs, such as miR-18a and b, miR-302, miR-193b, miR-22, and miR221/222 as well as miR-206, in the ERα 3'-UTR, and showed that these miRNAs inhibited estrogen signaling by directly targeting ERα mRNA (Leivonen et al., 2009; Pandey et al., 2009) (Fig.1).


Fig. 1. Schematic representation of the human ERα mRNA and the predicted miRNA target sites.

We recently analyzed expression levels of miRNAs that directly target ERα, including miR-18a, miR-18b, miR-22, miR-193b, miR-221/222 and miR-302c in human breast cancer

samples by quantitative RT-PCR analysis (Yoshimoto et al., 2011). Our results showed that miR-18a expression was much higher in ERα-negative than ERα-positive tumors, with the expression levels of miR-18a not differing in ERα-positive breast cancer as a function of ERα protein level. Surprisingly, expression levels of miR-193b and miR-221 were significantly lower in ERα-negative than ERα-positive tumors, and the levels of these miRNAs gradually increased as ERα protein expression increased. There was no statistically significant association between miR-22 and ERα expression, and miR-302c expression was minimal in human breast cancer samples. Prognostic analysis showed that low miR-18b expression was significantly associated with improved survival in HER2-negative breast cancer. Our results suggest that miRNAs that directly target ERα have distinct roles in not only regulating ERα but also regulating other target genes in human breast cancer, and that some miRNAs might be associated with characteristics of ERα-positive breast cancer.

2.3 Role of miRNAs in breast cancer

miRNAs can function as tumor suppressors and oncogenes (Esquela-Kerscher et al., 2006). The reduction or deletion of a miRNA that functions as a tumor suppressor leads to tumor formation. On the other hand, the amplification or overexpression of a miRNA that function as an oncogene results in tumor formation. Lu and colleagues first analyzed miRNA expression profiling in normal and tumor samples, and revealed global changes in miRNA expression (Lu et al., 2005). It was found that miRNA expression seems globally higher in normal tissues compared with tumors. Moreover, miRNAs are differentially expressed in various cancers. miRNA expression profiling also revealed that miRNAs are differently expressed among molecular subtypes in breast cancer (Blenkiron et al., 2007; Iorio et al., 2005). Iorio and colleagues first reported the miRNA gene expression profile in human breast cancer (Iorio et al., 2005). Compared with normal breast tissue, miRNAs are aberrantly expressed in human breast cancer. They also reported differentially expressed miRNAs associated with ERα expression, including miR-206. Blenkiron and colleagues analyzed miRNA expression in human breast cancer, and found that many miRNAs were differently expressed between breast cancer subtypes, such as luminal A, luminal B, HER2-positive, basal-like and normal-like (Blenkiron et al., 2007). They also found significant association between miRNA expression profiling and clinicopathological factors such as ERα status and tumor grade. Furthermore, recent studies have demonstrated that loss- or gain-of function of specific miRNAs contributes to breast epithelial cellular transformation and tumorigenesis. The interconnections between miRNAs and tumor suppressor genes and oncogenes in breast cancer were summarized by Zoon and colleagues (Zoon et al., 2009).

3. Conclusion

It is well recognized that individual miRNA sequences can suppress the production of hundreds of proteins (Krol et al., 2010). Reduction of protein levels in this way is often modest, however, and many such RNAs probably collectively fine-tune gene expression. Accumulating evidence supports the hypothesis that the ability of miRNAs to simultaneously regulate many target genes makes them attractive candidates for regulating normal and cancer cells. miRNAs are potential therapeutic targets for more tailored treatment strategies for breast cancer.

4. References

Adams BD, Cowee DM & White BA (2009). The role of miR-206 in the epidermal growth factor (EGF) induced repression of estrogen receptor-alpha (ERalpha) signaling and a luminal phenotype in MCF-7 breast cancer cells. *Mol Endocrinol,* Vol.23, No.8, pp. 1215-1230, ISSN 1944-9917

Adams BD, Furneaux H & White BA (2007). The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-alpha (ERalpha) and represses ERalpha messenger RNA and protein expression in breast cancer cell lines. *Mol Endocrinol,* Vol.21, No.5, pp. 1132-1147, ISSN 0888-8809

Allred DC, Brown P & Medina D (2004). The origins of estrogen receptor alpha-positive and estrogen receptor alpha-negative human breast cancer. *Breast Cancer Res,* Vol. 6, No. 6, pp. 240-245, ISSN 1465-542X

Allred DC, Harvey JM, Berardo M & Clark GM (1998). Prognostic and predictive factors in breast cancer by immunohistochemical analysis. *Mod Pathol,* Vol.11, No. 2, pp. 155-168, ISSN 0893-3952

Badve SS, Baehner FL, Gray RP, Childs BH, Maddala T, Liu ML, Rowley SC, Shak S, Perez EA, Shulman LJ, Martino S, Davidson NE, Sledge GW, Goldstein LJ & Sparano JA (2008). Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. *J Clin Oncol,* Vol.26, No. 15, pp. 2473-2481, ISSN 1527-7755

Blenkiron C, Goldstein LD, Thorne NP, Spiteri I, Chin SF, Dunning MJ, Barbosa-Morais NL, Teschendorff AE, Green AR, Ellis IO, Tavare S, Caldas C & Miska EA (2007). MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. *Genome Biol,* Vol.8, No. 10, pp. R214

Dowsett M, Allred C, Knox J, Quinn E, Salter J, Wale C, Cuzick J, Houghton J, Williams N, Mallon E, Bishop H, Ellis I, Larsimont D, Sasano H, Carder P, Cussac AL, Knox F, Speirs V, Forbes J & Buzdar A (2008). Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. *J Clin Oncol,* Vol. 26, No. 7, pp. 1059-1065

Ellis MJ, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Janicke F, Miller WR, Evans DB, Dugan M, Brady C, Quebe-Fehling E & Borgs M (2001). Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. *J Clin Oncol,* Vol. 19, No. 18, pp. 3808-3816

Endo Y, Toyama T, Takahashi S, Sugiura H, Yoshimoto N, Iwasa M, Kobayashi S, Fujii Y & Yamashita H (2011). High estrogen receptor expression and low Ki67 expression are associated with improved time to progression during first-line endocrine therapy with aromatase inhibitors in breast cancer. *Int J Clin Oncol,* ISSN 2547-7772, DOI 10.1007/s10147-011-0215-5

Esquela-Kerscher A & Slack FJ (2006). Oncomirs - microRNAs with a role in cancer. *Nat Rev Cancer,* Vol. 6, No. 4, pp. 259-269

Gaudet MM, Campan M, Figueroa JD, Yang XR, Lissowska J, Peplonska B, Brinton LA, Rimm DL, Laird PW, Garcia-Closas M & Sherman ME (2009). DNA hypermethylation of ESR1 and PGR in breast cancer: pathologic and epidemiologic

associations. *Cancer Epidemiol Biomarkers Prev,* Vol. 18, No. 22, pp. 3036-3043, ISSN 1538-7755

Giacinti L, Claudio PP, Lopez M & Giordano A (2006). Epigenetic information and estrogen receptor alpha expression in breast cancer. *Oncologist,* Vol. 11, No. 1, pp. 1-8

Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL & Wolff AC (2010). American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. *J Clin Oncol,* Vol. 28, No. 16, pp. 2784-2795

Harvey JM, Clark GM, Osborne CK & Allred DC (1999). Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. *J Clin Oncol,* Vol. 17, No. 5, pp. 1474-1481, ISSN 0732-183X

Herynk MH & Fuqua SA (2004). Estrogen receptor mutations in human disease. *Endocr Rev,* Vol. 25, No. 6, pp. 869-898

Holst F, Stahl PR, Ruiz C, Hellwinkel O, Jehan Z, Wendland M, Lebeau A, Terracciano L, Al-Kuraya K, Janicke F, Sauter G & Simon R (2007). Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. *Nat Genet,* Vol. 39, No. 5, pp. 655-660

Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, Menard S, Palazzo JP, Rosenberg A, Musiani P, Volinia S, Nenci I, Calin GA, Querzoli P, Negrini M & Croce CM (2005). MicroRNA gene expression deregulation in human breast cancer. *Cancer Res,* Vol. 65, No. 16, pp. 7065-7070, ISSN 0008-5472

Iwase H, Omoto Y, Iwata H, Toyama T, Hara Y, Ando Y, Ito Y, Fujii Y & Kobayashi S (1999). DNA methylation analysis at distal and proximal promoter regions of the oestrogen receptor gene in breast cancers. *Br J Cancer,* Vol. 80, No. 12, pp. 1982-1986, ISSN 0007-0920

Kondo N, Toyama T, Sugiura H, Fujii Y & Yamashita H (2008). miR-206 Expression is down-regulated in estrogen receptor alpha-positive human breast cancer. *Cancer Res,* Vol. 68, No. 13, pp. 5004-5008, ISSN 1538-7445

Krol J, Loedige I & Filipowicz W (2010). The widespread regulation of microRNA biogenesis, function and decay. *Nat Rev Genet,* Vol. 11, No. 9, pp. 597-610, ISSN 1471-0064

Leivonen SK, Makela R, Ostling P, Kohonen P, Haapa-Paananen S, Kleivi K, Enerly E, Aakula A, Hellstrom K, Sahlberg N, Kristensen VN, Borresen-Dale AL, Saviranta P, Perala M & Kallioniemi O (2009). Protein lysate microarray analysis to identify microRNAs regulating estrogen receptor signaling in breast cancer cell lines. *Oncogene,* Vol. 28, No. 44, pp. 3926-3936, ISSN 1476-5594

Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR & Golub TR (2005). MicroRNA expression profiles classify human cancers. *Nature,* Vol. 435, No. 7043, pp. 834-838, ISSN 1476-4687

Pandey DP & Picard D (2009). miR-22 inhibits estrogen signaling by directly targeting the estrogen receptor alpha mRNA. *Mol Cell Biol,* Vol.29, No. 13, pp. 3783-3790, ISSN 1098-5549

Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO & Botstein D (2000). Molecular portraits of human breast tumours. *Nature,* Vol. 406, No. 6797, pp. 747-752

Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lonning PE, Brown PO, Borresen-Dale AL & Botstein D (2003). Repeated observation of breast tumor subtypes in independent gene expression data sets. *Proc Natl Acad Sci U S A,* Vol. 100, No. 14, pp. 8418-8423

Tomita S, Zhang Z, Nakano M, Ibusuki M, Kawazoe T, Yamamoto Y & Iwase H (2009). Estrogen receptor alpha gene ESR1 amplification may predict endocrine therapy responsiveness in breast cancer patients. *Cancer Sci,* Vol. 100, No. 6, pp. 1012-1017, ISSN 1349-7006

Viale G, Regan MM, Maiorano E, Mastropasqua MG, Dell'Orto P, Rasmussen BB, Raffoul J, Neven P, Orosz Z, Braye S, Ohlschlegel C, Thurlimann B, Gelber RD, Castiglione-Gertsch M, Price KN, Goldhirsch A, Gusterson BA & Coates AS (2007). Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. *J Clin Oncol,* Vol. 25, No. 25, pp. 3846-3852, ISSN 1527-7755

Yamashita H, Iwase H, Toyama T, Takahashi S, Sugiura H, Yoshimoto N, Endo Y, Fujii Y & Kobayashi S (2011). Estrogen receptor-positive breast cancer in Japanese women: trends in incidence, characteristics, and prognosis. *Ann Oncol*, Vol. 22, No. 6, pp. 1318-1325, ISSN 1569-8041

Yamashita H, Takahashi S, Ito Y, Yamashita T, Ando Y, Toyama T, Sugiura H, Yoshimoto N, Kobayashi S, Fujii Y & Iwase H (2009). Predictors of response to exemestane as primary endocrine therapy in estrogen receptor-positive breast cancer. *Cancer Sci,* Vol. 100, No. 11, pp. 2028-2033, ISSN 1349-7006

Yamashita H, Ando Y, Nishio M, Zhang Z, Hamaguchi M, Mita K, Kobayashi S, Fujii Y & Iwase H (2006). Immunohistochemical evaluation of hormone receptor status for predicting response to endocrine therapy in metastatic breast cancer. *Breast Cancer*, Vol. 13, No. 1, pp. 74-83, ISSN 1340-6868

Yoshimoto N, Toyama T, Takahashi S, Sugiura H, Endo Y, Iwasa M, Fujii Y & Yamashita H (2011). Distinct expressions of microRNAs that directly target estrogen receptor α in human breast cancer. *Breast Cancer Res Treat*, online, DOI 10.1007/s10549-011-1672-2

Zhao JJ, Lin J, Yang H, Kong W, He L, Ma X, Coppola D & Cheng JQ (2008). MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. *J Biol Chem,* Vol. 283, No. 45, pp. 31079-31086, ISSN 0021-9258

Zoon CK, Starker EQ, Wilson AM, Emmert-Buck MR, Libutti SK & Tangrea MA (2009). Current molecular diagnostics of breast cancer and the potential incorporation of microRNA. *Expert Rev Mol Diagn,* Vol. 9, No. 5, pp. 455-467, ISSN 1744-8352

Breast Cancer - Carcinogenesis, Cell Growth and Signalling Pathways

Edited by Prof. Mehmet Gunduz

Cancer is the leading cause of death in most countries and its consequences result in huge economic, social and psychological burden. Breast cancer is the most frequently diagnosed cancer type and the leading cause of cancer death among females. In this book, we discussed various aspects of breast cancer carcinogenesis from clinics to its hormone-based as well as genetic-based etiologies for this deadly cancer. We hope that this book will contribute to the development of novel diagnostic as well as therapeutic approaches.

How to reference

In order to correctly reference this scholarly work, feel free to copy and paste the following:

Hiroko Yamashita, Tatsuya Toyama, Nobuyasu Yoshimoto, Yumi Endo, Mai Iwasa and Yoshitaka Fujii (2011). The Role of MicroRNAs in Estrogen Receptor α-Positive Human Breast Cancer, Breast Cancer - Carcinogenesis, Cell Growth and Signalling Pathways, Prof. Mehmet Gunduz (Ed.), ISBN: 978-953-307-714-7, InTech, Available from: http://www.intechopen.com/books/breast-cancer-carcinogenesis-cell-growth-and-signalling-pathways/the-role-of-micrornas-in-estrogen-receptor-positive-human-breast-cancer

INTECH
open science | open minds